We develop in parallel subcutaneous, oral, and transdermal delivery systems.

With multiple delivery methods in development, Starton can expand the number of medicines it is able to deliver continuously, based on patients’ individualized needs and provide multiple avenues for success.

Product Active Indication Preclinical Phase 1 Phase 1b Phase 2 Phase 3
STAR-LLD-SCsubcutaneous infusion
Lenalidomide
Standard Risk Relapsed Refractory Multiple Myeloma (RRMM)
STAR-LLD-OCRoral controlled release
Lenalidomide
Chronic lymphocytic leukemia (CLL)
STAR-LLD-OCRoral controlled release
Lenalidomide
High Risk Relapsed Refractory Multiple Myeloma (RRMM)
STAR-LLD-SCsubcutaneous infusion
Lenalidomide
Combination with CAR T cell therapies

STAR-LLD broadly refers to our lead candidate, a controlled delivery of low-dose lenalidomide which enables better tolerability, thus longer drug exposure at effective doses which may potentially improve PFS, OS, as well as quality of life.

STAR-LLD-SC is currently in Phase 2 testing for the treatment of relapsed/refractory multiple myeloma RRMM and represents the first clinical demonstration of Temporal Controlled Pharmacology. STAR-LLD is also being studied in Investigator Initiated Trials in in combination with both bispecifics and CAR-T cell therapies, in multiple myeloma and lymphoma.

Other active ingredients are being researched at our facility that have not yet been disclosed.

Powered by  GDPR Cookie Compliance (opens in a new tab)
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.